Related references
Note: Only part of the references are listed.Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
Yuichi Ando et al.
CANCER SCIENCE (2014)
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer
Leslie S. Bradford et al.
GYNECOLOGIC ONCOLOGY (2014)
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodon et al.
INVESTIGATIONAL NEW DRUGS (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Inhibition of Phosphatidylinositol 3-Kinase/AKT Signaling by NVP-BKM120 Promotes ABT-737-Induced Toxicity in a Caspase-Dependent Manner through Mitochondrial Dysfunction and DNA Damage Response in Established and Primary Cultured Glioblastoma Cells
Esther P. Jane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Howard A. Burris
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Antitumor Activity of NVP-BKM120-A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
Dimpy Koul et al.
CLINICAL CANCER RESEARCH (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Current clinical development of PI3K pathway inhibitors in glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2012)
Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model
Valerie L. Jacobs et al.
ASN NEURO (2011)
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Cesar G. Sanchez et al.
BREAST CANCER RESEARCH (2011)
A reproducible brain tumour model established from human glioblastoma biopsies
Jian Wang et al.
BMC CANCER (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype
T. -C. A. Johannessen et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2009)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
A Chakravarti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
